PTGS2 and glioblastoma: We investigated the potential roles of ALDOC, HTR2B, PTGS2, and NR2F1 along with various clinicopathological factors of GBM, including EGFR amplification, PTEN deletion, and chromosomal abnormalities (including codeletion of 1p/19q, gain of chromosome 7, and loss of chromosome 10).